SLANG Worldwide Inkomsten in het verleden
Verleden criteriumcontroles 0/6
SLANG Worldwide has been growing earnings at an average annual rate of 30%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 11.7% per year.
Belangrijke informatie
30.0%
Groei van de winst
50.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 23.1% |
| Inkomstengroei | 11.7% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -102.2% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Health Check: How Prudently Does SLANG Worldwide (CSE:SLNG) Use Debt?
Dec 26
Is SLANG Worldwide (CSE:SLNG) A Risky Investment?
Sep 09Is SLANG Worldwide (CSE:SLNG) A Risky Investment?
May 26Health Check: How Prudently Does SLANG Worldwide (CSE:SLNG) Use Debt?
Mar 28Is SLANG Worldwide (CSE:SLNG) Using Too Much Debt?
Dec 11The SLANG Worldwide (CSE:SLNG) Share Price Is Up 92% And Shareholders Are Holding On
Mar 02Opbrengsten en kosten
Hoe SLANG Worldwide geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 29 | -30 | 21 | 0 |
| 31 Mar 24 | 32 | -23 | 22 | 0 |
| 31 Dec 23 | 35 | -19 | 22 | 0 |
| 30 Sep 23 | 40 | -27 | 23 | 0 |
| 30 Jun 23 | 39 | -29 | 24 | 0 |
| 31 Mar 23 | 40 | -28 | 25 | 0 |
| 31 Dec 22 | 38 | -29 | 26 | 0 |
| 30 Sep 22 | 35 | -47 | 28 | 0 |
| 30 Jun 22 | 36 | -48 | 30 | 0 |
| 31 Mar 22 | 37 | -48 | 31 | 0 |
| 31 Dec 21 | 37 | -51 | 33 | 0 |
| 30 Sep 21 | 36 | -52 | 29 | 0 |
| 30 Jun 21 | 34 | -52 | 25 | 0 |
| 31 Mar 21 | 26 | -45 | 27 | 0 |
| 31 Dec 20 | 22 | -14 | 27 | 0 |
| 30 Sep 20 | 21 | -187 | 49 | 0 |
| 30 Jun 20 | 23 | -178 | 53 | 0 |
| 31 Mar 20 | 27 | -162 | 52 | 0 |
| 31 Dec 19 | 26 | -200 | 51 | 0 |
| 30 Sep 19 | 22 | 9 | 28 | 0 |
| 30 Jun 19 | 15 | -10 | 31 | 0 |
| 31 Mar 19 | 8 | -42 | 26 | 0 |
| 31 Dec 18 | 5 | -28 | 20 | 0 |
| 30 Sep 18 | 3 | -31 | 15 | 0 |
| 31 Dec 17 | 0 | -1 | 0 | 0 |
Kwaliteitswinsten: SLNG is currently unprofitable.
Groeiende winstmarge: SLNG is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: SLNG is unprofitable, but has reduced losses over the past 5 years at a rate of 30% per year.
Versnelling van de groei: Unable to compare SLNG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: SLNG is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Rendement op eigen vermogen
Hoge ROE: SLNG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.